Eyewear maker EssilorLuxottica signs perpetual Kodak brand license

Getting your Trinity Audio player ready...
EssilorLuxottica and Eastman Kodak Co. announced they have signed a perpetual worldwide license agreement, effecting Jan. 1, 2024, granting EssilorLuxottica the exclusive right to use the Kodak registered trademarks for products and services in connection with EssilorLuxottica’s business.

Other brands in the EssilorLuxottica portfolio include Armani, Ferrari, Brunello Cucinelli Casa di Moda, Coach, and more.

This new commitment represents an evolution of the multi-year licensing agreement with Kodak currently in place. Under the terms of the new agreement, EssilorLuxottica will continue to develop, manufacture and distribute optical products and services featuring the Kodak brand indefinitely.

“Kodak is an iconic brand rich in innovation and trusted by tens of millions of consumers around the world,” said Paul du Saillant, Deputy CEO of EssilorLuxottica.. We are pleased to make this substantial and permanent addition to our brand portfolio and are looking forward to leveraging our innovation capabilities and distribution network to create new opportunities for the brand and our customers. Long-term agreements like this one pave the way for our company’s growth for many years to come.”

“We are excited about the opportunity to expand our brand licensing arrangement with a vision care industry leader like EssilorLuxottica. We know the Kodak brand is in good hands along with the other esteemed brands in the EssilorLuxottica portfolio,” said Jim Continenza, Kodak’s Executive Chairman and CEO. “This agreement is a great fit for Kodak. We share EssilorLuxottica’s commitment to meeting evolving customer needs through innovation, and we look forward to a long and successful relationship.”

This isn’t the first time Eastman Kodak has licensed its name for eyewear; there is already Kodak Lens for prescription eyewear.

Polaroid has been selling eyewear for decades; currently, Polaroid Eyewear brand is owned by Sanofi.